Nov 30, 2020
Daniel O'Connor, CEO, OncoSec Immunotherapies describes their intratumoral therapy where the drug is injected directly into tumors instead of a systemic treatment thereby avoiding toxicities while also seeing tumors shrink that are not being directly treated, the abscopal effect. OncoSec is using electroporation to deliver interleukin-12 into cells. IL-12 is considered to be one of the most potent cytokines to fight cancer and their drug TAVO is being tested in conjunction with KEYTRUDA to help patients with melanoma not responding to current treatments.
@oncosec #oncology #cancer #interleukin-12 #IL-12 #melanoma #breastcancer #TAVO #immunotherapy $ONCS